Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2008 2
2012 4
2013 1
2014 3
2015 3
2016 1
2017 3
2018 2
2019 2
2021 5
2022 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, Arakawa Y, Gayle S, Jones K, Paralkar V, Sundaram RK, Van Doorn J, Vasquez JC, Bindra RS, Choi WS, Pommier Y. Jo U, et al. Among authors: sundaram rk. Mol Cancer Ther. 2022 Jul 5;21(7):1090-1102. doi: 10.1158/1535-7163.MCT-21-1000. Mol Cancer Ther. 2022. PMID: 35439320 Free PMC article.
Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy.
Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, Boutros P, Bindra RS, Shuch B. Ueno D, et al. Among authors: sundaram r. Oncotarget. 2022 Sep 14;13:1054-1067. doi: 10.18632/oncotarget.28273. eCollection 2022. Oncotarget. 2022. PMID: 36128328 Free PMC article.
Protein stains and applications.
Sundaram RK, Balasubramaniyan N, Sundaram P. Sundaram RK, et al. Methods Mol Biol. 2012;869:451-64. doi: 10.1007/978-1-61779-821-4_39. Methods Mol Biol. 2012. PMID: 22585510
In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. Gbyli R, et al. Among authors: sundaram r. Leukemia. 2022 May;36(5):1313-1323. doi: 10.1038/s41375-022-01536-x. Epub 2022 Mar 10. Leukemia. 2022. PMID: 35273342 Free PMC article.
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Jackson CB, Noorbakhsh SI, Sundaram RK, Kalathil AN, Ganesa S, Jia L, Breslin H, Burgenske DM, Gilad O, Sarkaria JN, Bindra RS. Jackson CB, et al. Among authors: sundaram rk. Cancer Res. 2019 Sep 1;79(17):4331-4338. doi: 10.1158/0008-5472.CAN-18-3394. Epub 2019 Jul 4. Cancer Res. 2019. PMID: 31273061 Free PMC article.
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity.
Garbarino J, Eckroate J, Sundaram RK, Jensen RB, Bindra RS. Garbarino J, et al. Among authors: sundaram rk. Transl Oncol. 2021 Sep;14(9):101147. doi: 10.1016/j.tranon.2021.101147. Epub 2021 Jun 9. Transl Oncol. 2021. PMID: 34118569 Free PMC article.
31 results